AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

A securities class action alleges that Aardvark Therapeutics omitted material ARD-101 safety risks from its February 2025 IPO registration statement before the FDA imposed a full clinical hold on the drug candidate. Aardvark raised $87.6 million net through the $16 IPO, but shares closed at $4.57 on May 15, 2026—down 71.4%, or $11.43 per share—following a Phase 3 HERO trial pause tied to reversible cardiac observations and the subsequent FDA hold. Investors seeking lead-plaintiff status must file by October 13, 2026.

Analysis

The lawsuit itself is not a new fundamental catalyst; plaintiff-firm announcements typically create limited incremental liability because damages are generally capped by issuer resources and D&O coverage. The investable issue is that an alleged omission claim can complicate any equity raise precisely when AARD may need incremental capital to restart development, raising the probability of a discounted financing, warrant overhang, or strategic transaction. With a lead asset under a full FDA hold, enterprise value should be assessed against net cash and residual platform value rather than a conventional probability-adjusted Phase 3 timeline.

Near term, the October lead-plaintiff deadline is unlikely to alter valuation absent a company response, new clinical disclosure, or an additional regulatory filing. Over 1-3 months, the critical catalyst is whether FDA identifies a remediable dose/exposure issue versus a broader cardiac-safety signal; a protocol amendment or hold release would force a sharp repricing, while continued silence increases financing-risk discounting. The contrarian point is that the equity may already reflect high failure odds, so a fresh short based solely on litigation has poor asymmetry unless current market capitalization remains materially above net cash; the more durable downside comes from a cash burn and restart-duration mismatch, not eventual legal damages.

Key Decisions for Investors

• Do not initiate a directional position from the class-action release alone; treat it as a governance/financing-risk flag rather than a standalone catalyst.
• Place AARD on a regulatory alert: reassess immediately upon FDA hold correspondence, a disclosed restart protocol, or updated cardiac-safety data. A hold release with a credible lower-exposure dosing path would falsify a bearish operating thesis and could drive a multi-day squeeze.
• For a bearish position, require verification that AARD's current enterprise value exceeds cash materially, quarterly operating cash burn remains elevated, and stock borrow is available; then consider a 1-3 month short or put spread sized for binary regulatory upside. Cover if management provides a funded runway through a revised pivotal-data readout or the FDA permits enrollment restart.
• Monitor follow-on financing language in the next 10-Q/10-K and any shelf registration. A dilutive raise before regulatory clarity is the highest-probability 3-6 month negative catalyst; absence of a financing need materially weakens the short case.